Answers you can use to understand the findings
What 22 retatrutide answers explain about treatment limits
Lilly hoped retatrutide could improve weight and diabetes together. Phase 1 early tests, Phase 2 middle tests, and Phase 3 larger tests help answer your questions.
What stopping retatrutide might change about your weight
Weight returned after people stopped related medicines, raising a concern that matters to your health. A 2025 study examined liraglutide, semaglutide, and tirzepatide [7], but didn't test stopping retatrutide.
Authors reviewing findings in 2026 also described weight returning with this drug family [13]. By mid-2026, retatrutide had no published stopping results from Phase 3, the larger tests before possible approval.
What does retatrutide do to hunger and body weight?
In the middle tests, called Phase 2, average loss reached 24.2% with weekly 12 milligram shots during the 48-week trial. Placebo, treatment without retatrutide, produced 2.1% loss [1], with each loss measured from starting weight.
Retatrutide copies GLP-1 and other hormones, your body's messengers, to curb hunger, release insulin, and burn calories. A 2025 review called the findings a major advance [6], though the average can't promise your result.
How does retatrutide work on hunger and blood sugar?
The drug copies GLP-1, a hunger hormone, and other hormones managing insulin release and calorie burning. Microscopes showed retatrutide touching cells that respond to these hormones [3], but cells can't show your likely weight loss.
Blood checks found half the drug still present after a ~6-day period [4], supporting weekly injections in studies. A longer stay in blood doesn't establish a safe shot schedule outside a trial.
Why retatrutide powder has no approved mixing method
Trial staff provided prepared medicine, rather than asking people to add liquid to freeze-dried powder. Those strict drug-making conditions don't establish a safe way to mix powder from an outside seller.
Such powder hasn't been confirmed as genuine retatrutide or free of harmful substances. You can't learn the contents by dissolving the powder, and no outside mixing method has approval.
Is retatrutide FDA approved for your doctor to prescribe?
The FDA, the United States agency reviewing medicines, hadn't approved retatrutide by mid-2026, and neither had any other country. Phase 3, the larger tests called TRIUMPH, continued without an approved retatrutide prescription for you.
Results from the first Phase 3 test appeared in 2026 [12], with more studies still underway. Finished findings need official review before a doctor could prescribe an approved retatrutide medicine.
When will retatrutide be available for approved treatment?
Phase 3, larger tests before possible approval, continued without a confirmed pharmacy date. If Eli Lilly finishes Phase 3 and receives FDA approval, supply might follow in 2027–2028.
The FDA could ask for more evidence before deciding whether to approve the drug. You can't plan care around that estimated year, even if the studies finish on time.
What happened when people received retatrutide in trials
Trial staff gave prepared retatrutide by weekly injection beneath the skin under strict drug-making standards. Doctors increased amounts gradually over weeks to reduce sick stomachs and other gut problems.
Retatrutide remains unapproved, and these studies involved medical checks throughout treatment. The study procedures aren't approved instructions for your own shot amounts, timing, or preparation.
How long does retatrutide take to work on the scale?
Weight fell early in Phase 2, the middle tests, and kept falling through the 48-week trial [1]. With 12 milligrams, average loss reached about 17–18% by week 24 and 24.2% by week 48.
These 48-week averages can't establish when you would notice a change or what you would lose. Sugar and liver fat improved by week 24 [2][5]; how long does retatrutide take to work explains those findings.
What separate studies suggest about retatrutide compared with tirzepatide
Retatrutide's Phase 2 middle tests suggest greater weight loss than tirzepatide's Phase 3 larger tests [8]. Separate groups with different care leave the choice of which works better unsettled for you.
The direct TRIUMPH comparison hadn't published results by mid-2026 [8]. A 2026 review also described weight returning after treatment stopped as a concern for both medicines [13].
What weekly retatrutide amounts mean within a study
In Phase 2, the middle tests, doctors gave weekly amounts of 1, 4, 8, or 12 milligrams [1]. Phase 3, larger tests, used 12 milligrams weekly after planned increases [12].
These were amounts checked during closely watched studies, rather than an approved prescription plan. The numbers can't choose a safe retatrutide amount for you, and no prescription use has approval.
Why adding water cannot check what retatrutide powder contains
The trials used medicine prepared to strict drug-making standards before people received injections. No method has approval for mixing outside retatrutide powder with water, even water sold for preparing shots.
The bottle's label cannot confirm genuine drug or freedom from harmful substances. Mixing instructions aren't offered here because adding water can't establish what would enter your body.
What remains unknown when switching from tirzepatide to retatrutide
No published study instructions covered switching from tirzepatide to retatrutide as of mid-2026. Tirzepatide has FDA approval, while retatrutide lacks an approved prescription option for your care.
Both copy GLP-1, a hunger hormone, and GIP, which helps release insulin; retatrutide also copies glucagon to burn calories. These papers can't replace a doctor's assessment of your health when considering a change of treatment.
What the mistaken name GLP-3 suggests about retatrutide
Calling retatrutide “GLP-3” suggests a hormone that doesn't exist in the human body. Some popular reports use “GLP-3,” but that name misstates how the drug works.
Retatrutide copies GLP-1 to reduce hunger, GIP to help release insulin, and glucagon to burn calories [3]. All are hormones, messengers inside your body; “GLP-3” incorrectly points to a different hormone.
Why outside retatrutide sales do not mean approved supply
By mid-2026, retatrutide had no approval as a prescription or lawful commercial medicine in any country. Outside sellers nevertheless offered research bottles, which aren't approved treatment options for you.
The labels don't prove genuine retatrutide, the claimed amount, or freedom from harmful substances. FDA warning letters challenged those sales; you can read the health concerns about unchecked bottles on the effects page.
What retatrutide studies tried to improve in the body
Studies in obesity, type 2 diabetes, and fatty liver found lower weight, better sugar control, and less liver fat [1][2][5]. These findings explain interest in the drug, but don't establish approved uses for your care.
Phase 3, larger tests before possible approval, also examines heart health and long-lasting kidney disease. No retatrutide use has approval, so a promising finding alone cannot become an approved treatment choice.
What retatrutide tests measured in cells rather than people
A microscope study examined retatrutide touching cells that respond to GLP-1 and other hormones [3]. These hormones help manage hunger, insulin release, and calorie burning inside your body.
Researchers measured how strongly the drug made those cells react in a dish. That test didn't measure people's strength, hunger, or weight loss; those answers require people to be studied.
What retatrutide laws leave uncertain about personal use
In mid-2026, retatrutide wasn't a controlled drug with special possession rules, such as some strong painkillers. Its lack of approval still made commercial sales or supply outside trials unlawful under federal drug law.
FDA warning letters told sellers their sales broke the Federal Food, Drug, and Cosmetic Act. A research label couldn't remove the legal rules that applied to selling and supplying the drug.
Keeping retatrutide for personal experiments remained legally uncertain, with no publicly reported court ruling. Giving yourself shots doesn't make you a trial member, and that uncertainty doesn't establish legal permission.
What weekly retatrutide injections meant under study care
Completed trials gave weekly injections beneath the skin with medical checks throughout treatment [1][2][4]. After a ~6-day period, blood still held about half the drug [4], supporting the weekly timing.
TRIUMPH's Phase 3 larger tests also use weekly shots under medical care. You can understand the trial timing without treating that timing as a safe schedule outside a study.
How long retatrutide stayed in blood in early checks
Phase 1b, early tests, found half the retatrutide still in blood after about 6 days [4]. Added fat lets a protein in blood carry retatrutide, helping the drug stay there longer.
Blood proteins carry medicines and other substances, and carrying retatrutide slows removal from your body. The finding helped researchers choose weekly rather than daily shots, without setting an approved schedule for you.
Why refrigerating retatrutide cannot confirm a safe shot
Trial staff kept prepared retatrutide at 2–8°C, meaning the cold range in a refrigerator, above freezing, and used a set expiry date. Those checks protected known medicine; your outside bottle has no approved storage rules.
Heat, freezing and thawing, and moisture can damage related drugs and reduce their effects. Refrigeration can't prove that an outside bottle holds genuine, undamaged retatrutide in the stated amount.
What distinguishes retatrutide from Ozempic
Ozempic contains semaglutide, a medicine copying GLP-1, the hormone action that reduces hunger. Retatrutide adds GIP's help with insulin release and glucagon's help with calorie burning [3].
Semaglutide has FDA approval, from the agency reviewing medicines, while retatrutide has none. The related drugs aren't the same medicine, so their names describe different treatment choices for you.
What retatrutide and semaglutide findings cannot settle
Retatrutide's Phase 2 middle tests found loss of 24.2% with 12 milligrams over 48 weeks [1][6]. Semaglutide's Phase 3 larger tests found less loss, but separate studies cannot decide which would benefit you more.
A 2026 review described weight returning after stopping as a concern with this drug family [13]. No trial compared the drugs directly; glucagon's extra calorie burning remained a possible advantage awaiting proof.